Canadian Securities ExchangeThe Daily Bell

Timothy Ko on Treating Addiction with DMT and Psychedelics

September 10, 2021

About This Video

CSE's Barrington Miller catches up with Timothy Ko, CEO of Entheon Biomedical Corp. (CSE:ENBI) to discuss how his company is pursuing R&D of DMT-based products to safely treat addiction. Timothy provides an update on what the company has accomplished in the year since they've been public and upcoming plans for clinical trials.

Here's an overview of what Barrington and Timothy cover in this edition of the "Exchange for Entrepreneurs" podcast:

0:00 - Catching up with Timothy Ko and Entheon Biomedical

2:30 - What has happened since they listed on the CSE - Canadian Securities Exchange

4:12 - Personalization through genetics

6:20 - The genetics test kit

8:30 - Pathway for clinical trials

9:55 - What's coming next for investors

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe

STAY CONNECTED WITH THE CSE

=============================

- PODCAST: https://blog.thecse.com/cse-podcasts/

- INSTAGRAM: https://www.instagram.com/canadianexchange/

- LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange

- FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/

- TWITTER: https://twitter.com/CSE_News

- BLOG: https://blog.thecse.com/

- WEBSITE: https://thecse.com/

MB01SQFQRO51BEN

Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.

hi welcome to updated listing clip with timothy koh ceo of antheon welcome to the show even though it's not your first time here it's a pleasure to be here again for our audience if you've been following the cse whether it's on youtube instagram linkedin or facebook you'll know that we have a segment called newly listed clips well entheon was on i'm gonna say roughly a

year ago and we thought it's about time to catch up with timothy and see what's been happening what's new and we're we're here so timothy please just tell our audience for those who don't know you what it is anthony does and your role with the company yeah pleased to be here again barrington so anthon is in the drug development space we're trying to develop dmt based

drugs for the purposes of treating addiction so that's our core focus we have a drug development program and clinical trials planned for late q4 of this year using the very powerful psychoactive molecule known as dmt or dimethyltryptamine and the premise behind that is that for those that suffer from addiction there is generally sort of internal subject matter material that they're not able to really access that dmt through the purpose of its

mechanism of action is able to elicit and bring to the surface thereby allowing an individual that is maybe you know not dealing with their issues their emotions their memories their traumas to actually have an experience around that to shape entirely new perspectives around these things that for whatever reason they may not have been able to address recently in the last couple of years there have been a

growing wealth of evidence of things like psychedelics and psilocybin for instance are very effective in eliciting these things and that's been very useful in the realm of treatment treatment resistant depression major depressive disorders and we believe that based on literature that we've looked at there is also a very strong case to be made for dmt in treating addiction-based issues and so that's our core focus i'm sure we'll have some time

to get into some of our other focuses but at present yeah dmt drug development for the purpose of treating addiction wow and that's fascinating you've been a public company now for 365 days where do you see yourself in the in the larger scheme of things within the within the sector within the industry yeah absolutely you know since we listed there have been there's been a huge cambrian

explosion of interest in the psychedelic space and so like us there have been a multitude of other companies entering the drug development space developing their own novel molecules or forms of administering those molecules for a variety of mental health conditions and i do believe that a lot of these companies do have a very firm foundation upon which to stand but that being said there is some some amount of siloing in terms of which

molecule for which specific indication of which you know we also have dmt which we believe is the most safe and flexible molecule for the purpose of treating addiction we also see dmt in a variety of other mental health spaces as well as a variety of other molecules in a variety of mental health spaces and so what we're seeing is a bit of a sort of siloing sort of effort taking place

where there are dozens of companies proposing these drugs for a variety of mental health conditions and a lot of them will likely see approvals as we also hope ours will that being said and theon has taken a look at the landscape and you know surmise that though all these amazing development efforts are taking place there isn't enough put effort put forward in terms of personalization safety and so that's an

area that antion is very much committed to and so if anyone's been keeping track of our news releases that have been going on our corporate developments we're taking a very committed approach to personalization in the genetic space as well as within electro neurophysiology and these are sort of big words and big concepts but the premise is that we believe that as the science evolves and as we evolve our understanding of the

literature as well as clinical research we can use genetics to further enhance our understanding of individual patient variability understanding that you know you and i we may respond differently to a variety of drugs as well as we you know we may possess different risk factors for specific you know negative adverse events and so we're taking the position of evolving with our evolving genetics as the science evolves

to better characterize who is appropriate to take a variety of psychedelic medicines so we acquired a company called halogen life sciences as well as recently acquired a company called lobo genetics to further that aim to advance our understanding of genetics not only to service our own dmt development efforts but to service the already existing psychedelic therapy space as well as the broader psychedelic space as it comes online over the course

of the next five or ten years so the genetics testing as we develop it further is intended to you know provide patients as well as physicians a better understanding of what the risk factors and appropriate drugs are whether that's ketamine or psilocybin or mdma we're trying to develop a additional safety protocol or safety layer so that you know ultimately that individual that's taking a very brave step of

saying i want to get better i'm you know maybe acknowledging for the first time that i'm tired of feeling the way that i feel entheon is really committed to capitalizing on that moment of willingness and ensuring that they don't waste their time getting ineffective treatments or drugs that aren't appropriate for them or at the worst drugs that might elicit negative adverse events for them and so we're committed to personalization in

that regard and so yeah we're trying to be collaborative and service the broader psychedelic industry not just our own internal siloed aims now what about the genetics test kit does that fall in to what you're doing and can you elaborate just a little bit on that absolutely yeah the genetics test kit is currently available within canada and the us we only recently launched in the u.s

and since its launch and sort of public visibility we have seen a very dramatic increase in terms of interest we're working on a variety of commercial partnerships as well as research-based partnerships those are advancing where there are and yeah there's a growing interest in terms of knowing how genetics might affect someone that's going in to receive the ketamine treatment right now our genetic test kit is focused on five biomarkers and we're

looking to expand that and we're in the process of recruiting additional advisory firepower to inform that process but presently what the genetic test kit looks at is a variety of biomarkers that are associated with increased risk of psychiatric disorders understanding that there are certain psychedelics in certain people that can elicit a psychosis or a schizophrenia response and then additionally there are metabolic factors that will indicate whether an individual is more or less

likely to have a strong metabolic response or a weak metabolic response ultimately potentially contributing to whether a person has a stronger or weaker than intended drug treatment that might result in you know unexpected therapeutic outcomes and so yeah that's what the kit presently looks for within the ketamine ketamine bucket as well as within the broader serotonergic bucket and of course you know science evolves on continuous basis we've recently seen

mind med identify a biomarker that is specific to lsd metabolism and so we're constantly looking to include more information and refinement into this test and iterate it and evolve it as the science gets produced and as we produce the science seems like something new is coming out every single day to further enhance our knowledge and understanding with this and to that end clinical trials these are these are expensive how is

your cash position we're currently sitting on approximately 3.5 million dollars so that's you know it's adequate for us to carry out our current endeavors and development plans that being said we do understand obviously that the full clinical development pathway takes multiple rounds of clinical trials you know for which there are hundreds if not thousands of patients that require to be recruited so you know inevitably we

will need to go back to the market for additional financing but you know we are trying to progress and de-risk as much as we can and so to that end we have pre-clinical and clinical trials planned for initiation prior to the end of the year and we're very confident based on literature that you know the results of that will demonstrably show that there is

safe usage of dmt in humans and then following that there are a variety of additional efficacy trials within the nicotine opiate and alcoholism space that we're pursuing for which of course we will need to go back to the market to you know request additional financing and of course you can't do it alone looks like you're surrounding yourself with some pretty smart people and a good team what is next on the horizon

for antheon yeah with a lot of really interesting developments super exciting for us for those that are in the know or have been paying attention we've recently announced a an observational study with heading health just to sort of exemplify some of our ambitions in terms of the biomarker discovery space we are engaging in a trial or a study with heading health is an

austin-based ketamine clinic we're going to be taking a look at eeg or electroencephalogram looking at the neurophysiology of an individual as they undergo a ketamine experience and we're also going to be looking at a genetic genetic associated differential response to see that if if there are people that possess these specific ketamine biomarkers or ketamine metabolism biomarkers whether they have a stronger or a weaker subjective experience and the really interesting thing there

is the investigation of the brain activity as an individual undergoes the the ketamine state understanding that there's a lot still unknown about what constitutes a psychedelic experience it sort of defied poets and philosophers and scientists for a very long time and so we are engaging in an observation of what happens at the brain level under that state with the ambition of creating a diagnostic tool you know in

ketamine as well as a variety of other drug classes to better understand what are the expected biomarkers that a person experiences or that are present within that drug experience so that we can start you know establishing what the expectations are for a normal psychedelic experience so that we can give physicians additional visibility as to where that person is in this often difficult to characterize state so that we can establish what is safe

what is therapeutic and help provide some guide rails and additional visibility to make that situation or that experience even safer for individuals that are undergoing those experiences well timothy i just want to say thank you on behalf of the canadian securities exchange for your continued listing and as well as as well your support we admire what you and your team are doing and trying to help the world and

make it a better place and a safer place and a healing place i've been your host barrington miller this has been an episode of updated clip and i was here with timothy cole from anthony thank you and we'll see you at the next update

you